# EDGAR Filing Document

**Accession Number:** 0002028614
**File Stem:** 0001213900-26-041284
**Filing Date:** 2026-4
**Character Count:** 9847
**Document Hash:** 9db758bcf4acd2c589ad83921d33ab28
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-041284.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001213900-26-041284

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260407

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition Corp.
- **CENTRAL INDEX KEY:** 0002028614
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42467
- **FILM NUMBER:** 26846647

**BUSINESS ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE
- **STREET 2:** SUITE 1402
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE
- **STREET 2:** SUITE 1402
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d) of the**

**Securities Exchange Act of 1934**

**April 7, 2026**

Date of Report (Date of earliest event reported)

**Drugs Made In America Acquisition Corp.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-42467** | **99-2394788** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification Number) |

---

---

| | |
|:---|:---|
| **420 Lexington Avenue, Suite 1402**<br> **New York, NY** | **10170** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**646-726-7074**

Registrant's telephone number, including area code:

**1 East Broward Boulevard; Suite 700**

**Fort Lauderdale, FL 33301**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one Ordinary share, $0.0001 par value and one right to receive one-eighth of one ordinary share | DMAAU | The Nasdaq Stock Market LLC |
| Ordinary shares, par value $0.0001 per share | DMAA | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-eighth of one Ordinary Share | DMAAR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events**

On April 7, 2026, Drugs Made in America Acquisition Corp. (the "Company") entered into a letter of intent (the "LOI") with Power Analytics Global Corp., a Delaware corporation (the "Target") for a de-SPAC transaction resulting in Target becoming a public company. The terms of the transaction are subject to further negotiation and execution of a business combination agreement although it is anticipated that the valuation for Target will be approximately $1.0 billion, subject to adjustment based on due diligence, capital structure, net debt, working capital and market conditions. A copy of the Letter of Intent is filed as Exhibit 10.1 hereto and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 10.1 | [Letter of Intent](ea028552701ex10-1.htm) |
| 104 | Cover Page Interactive Data File |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 8, 2026

---

| | |
|:---|:---|
| **DRUGS MADE IN AMERICA ACQUISITION CORP.** | **DRUGS MADE IN AMERICA ACQUISITION CORP.** |
| By: | /s/ Roger Bendelac |
| Name: | Roger Bendelac |
| Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

LETTER OF INTENT

Proposed Business Combination

Power Analytics Global Corp ("PAGC")

and

Drugs Made in America Acquisition Corp ("DMAA")

Dated: April 7, 2026

**SECTION 1 – PARTIES**

Power Analytics Global Corp ("PAGC"), a Delaware corporation.

Drugs Made in America Acquisition Corp ("DMAA"), a Cayman Islands exempted company and publicly traded special purpose acquisition company listed on Nasdaq.

**SECTION 2 – PROPOSED TRANSACTION STRUCTURE**

The Parties intend to enter into a definitive business combination agreement (the "Business Combination Agreement") pursuant to which PAGC shall combine with DMAA in a transaction intended to qualify as a de-SPAC transaction, resulting in PAGC becoming a publicly listed company.

The structure, including merger mechanics, equity consideration, and governance, shall be set forth in the Business Combination Agreement and related SEC filings, including a registration statement on Form S-4.

**SECTION 3 – VALUATION AND CONSIDERATION**

The transaction is expected to reflect an implied equity valuation of approximately $1,000,000,000 for PAGC, subject to customary adjustments based on due diligence, capital structure, net debt, working capital, and market conditions.

Final consideration, including share exchange ratios and potential earn-out provisions, shall be determined in the Business Combination Agreement.

**SECTION 4 – TRUST ACCOUNT; NON-RECOURSE (S-4 ALIGNED)**

DMAA maintains a trust account for the benefit of its public shareholders (the "Trust Account").

In accordance with customary SPAC practice and to be reflected in the Business Combination Agreement and Form S-4, no party hereto shall have any right, title, interest, or claim of any kind in or to the Trust Account, except as expressly provided under applicable securities laws and the governing trust agreement.

The Trust Account shall not be used to satisfy any liabilities, obligations, or claims arising out of this Letter of Intent or the transactions contemplated hereby.

**SECTION 5 – WAIVER OF CLAIMS AGAINST TRUST (MARKET STANDARD)**

PAGC agrees that it shall not seek recourse against the Trust Account or any funds held therein for any reason, including any claim arising out of this Letter of Intent, the Business Combination Agreement, or the transactions contemplated thereby.

This provision is intended to be consistent with standard SPAC transaction documentation and shall be incorporated into definitive agreements.

**SECTION 6 – EXTENSION AND SPONSOR SUPPORT**

The Parties acknowledge that DMAA may require stockholder approval to extend its business combination deadline.

PAGC and/or its affiliates may support such extension through contributions or arrangements to be defined in definitive documentation.

**SECTION 7 – MINIMUM CASH CONDITION**

The Business Combination Agreement is expected to include a minimum cash condition, anticipated to be in the range of $25,000,000 to $50,000,000, subject to redemptions and final negotiation.

**SECTION 8 – FINANCING AND PIPE**

The Parties may pursue additional financing, including PIPE investments or other capital raising transactions, the terms of which shall be set forth in definitive agreements.

Such financing shall be independent of the Trust Account unless otherwise expressly agreed.

**SECTION 9 – SEC PROCESS AND DISCLOSURE**

The Parties intend to prepare and file with the SEC a registration statement on Form S-4 (or equivalent), including a proxy statement/prospectus, reflecting the terms of the Business Combination Agreement.

All financial statements, pro forma information, and disclosures shall be prepared in accordance with applicable SEC rules and PCAOB standards.

**SECTION 10 – THIRD PARTY BENEFICIARY**

The trustee of the Trust Account and its beneficiaries shall be entitled to rely on and enforce Sections 4 and 5.

**SECTION 11 – CONFIDENTIALITY**

The existence and terms of this Letter of Intent and all discussions shall remain confidential, except as required by law or SEC disclosure obligations.

**SECTION 12 – NON-BINDING; TRANSITION TO DEFINITIVE AGREEMENTS**

This Letter of Intent is non-binding except for Sections 4, 5, 10, and 11.

The Parties agree to negotiate in good faith to enter into a definitive Business Combination Agreement, which shall supersede this Letter of Intent in its entirety.

**SIGNATURES**

POWER ANALYTICS GLOBAL CORP

---

| | |
|:---|:---|
| By: | /s/ Keith Barksdale |
| Name: | Keith Barksdale |
| Title: | Chairman |

---

DRUGS MADE IN AMERICA ACQUISITION CORP

---

| | |
|:---|:---|
| By: | /s/ Roger Bendelac |
| Name: | Roger Bendelac |
| Title: | CEO |

---